Vivante Concludes Process Optimisation Contract For Oxford University’ Malaria Vaccine

Vivante GMP Solutions (Vivante) has completed process optimisation activities related to the upcoming production of a GMP clinical lot of an Oxford University adenovirus-based malaria vaccine.

Reportedly, the Jenner Institute at Oxford University is involved in multiple vaccine projects for various infectious diseases. These programs are funded in part by the European Malaria Vaccine Initiative and the Grand Challenges in Global Health (GCGH) initiative. The GCGH is jointly funded by the Bill and Melinda Gates Foundation, the Wellcome Trust, and the Canadian Institute of Health Research.

David Enloe, president and CEO at Vivante, said: “We are very pleased to be working with Oxford on this important project. Oxford has multiple vaccine initiatives which represent the next generation of addressing many serious public health threats. The work Vivante has done thus far to optimise this product’s GMP production process is something our team is very proud of.”

Adrian Hill, director of the Jenner Institute and chairman of the Centre for Clinical Vaccinology and Tropical Medicine at Oxford University, said: “Vivante has been important to the Jenner Institute in our development of new approaches to vaccinating against malaria. I look forward to a growing relationship with Vivante as these programs progress through clinical trials.”